Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,082 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Lymphoma, Hodgkin's Disease, Hematologic Neoplasms, Multiple Myeloma, Carcinoma, Renal Cell
Interventions
Pentostatin, Alemtuzumab, Allogeneic hematopoietic stem cell transplantation
Drug · Biological · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Tucson, Arizona
Conditions
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Interventions
sirolimus
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
glecaprevir/pibrentasvir treatment
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more
Conditions
Islet Cell Transplantation, Type 1 Diabetes
Interventions
Islet cell transplantation
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Graft Rejection, Kidney Disease
Interventions
Alemtuzumab and DSG
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
End Stage Renal Disease
Interventions
Transplant navigator, Usual care
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 70 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 4 Interventional Results available

Desensitization in Kidney Transplantation

NCT00908583
Conditions
HLA Sensitization
Interventions
plasmapheresis, Bortezomib, Rituximab, Methylprednisolone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Cincinnati, Ohio
Conditions
Herpes Zoster
Interventions
Live attenuated herpes zoster vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Nashville, Tennessee
Conditions
Kidney Transplant Rejection
Interventions
AlloSure
Device
Lead sponsor
CareDx
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
8
States / cities
Aurora, Colorado • Tampa, Florida • Baltimore, Maryland + 5 more
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Cytomegalovirus Disease
Interventions
NPC-21 Low dose, NPC-21 High dose, NPC-21 Placebo
Drug
Lead sponsor
Nobelpharma
Industry
Eligibility
18 Years to 76 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more
Conditions
Delayed Graft Function
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Conditions
Kidney Diseases
Interventions
Anti-thymocyte globulin, Mycophenolate mofetil, Prednisone, Tacrolimus, Sirolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Renal Failure, Medication Adherence, Hypertension
Interventions
mHealth
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Autoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
Interventions
Therapeutic plasma exchange
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • Rochester, Minnesota • Charlottesville, Virginia + 1 more
Conditions
Chronic Kidney Diseases
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Not applicable Interventional Results available

Disparities in National Kidney Allocation Policy

NCT02879812
Conditions
Kidney Disorders
Interventions
Performance Feedback Reports, Educational Video for Staff, Educational Video for Patients, Educational Webinar, Standard Care, United Network for Organ Sharing (UNOS) Pamphlet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
56,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Graft Rejection, Kidney Transplantation
Interventions
plasmapheresis and IVIG, recombinant C1 inhibitor
Procedure · Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Cancer
Interventions
DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
Genetic · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Autoimmune Diseases
Interventions
Efalizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
End Stage Renal Disease, End Stage Liver Disease
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
13,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
End Stage Renal Disease
Interventions
Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Gainesville, Florida • Miami, Florida + 8 more
Conditions
Delayed Graft Function
Interventions
OPN-305, Placebo
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more